A chemogenomic screen coupling PLK1 inhibition and genome-wide gene knockout in melanoma cells could be useful to precisely identify sensitization or desensitization factors that could explain therapeutic resistance or help better position PLK1 inhibitors. Here, PLK1 is linked to melanoma.